Everolimus-evertor (5mg, 10mg): Check Drug Details and Specifications

Indication

Everolimus is commonly prescribed in kidney and / or liver transplanted, renal cancer patients.

Medical Uses:

Everolimus is approved for various conditions:

• Advanced kidney cancer (US FDA approved in March 2009)
• Prevention of organ rejection after renal transplant (US FDA April 2010)
• Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention (US FDA October 2010)
• Progressive or metastatic pancreatic neuroendocrine Tumors not surgically removable (May 2011)
• Breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer, in conjunction with Exemestane (US FDA July 2012)
• Prevention of organ rejection after liver transplant(Feb 2013)
• Progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease (US FDA February 2016).
• Tuberous sclerosis compex-associated partial-onset seizures for adult and Pediatric patients aged 2 years and older. (US FDA April 2018).

Note

SIDE EFFECTS :

Non-Infectious Pneumonitis, Infections, Severe Hypersensitivity reactions, Angioedema, Renal Failure.

INTERACTION :

• Avoid the concomitant use of P-gp and strong CYP3A4 inhibitors.
• Patients taking concomitant ACE inhibitors with Everolimus may be at increased risk for angioedema. Avoid the concomitant use of ACE inhibitors with Everolimus. 

OVERDOSE :

• Do not use more than prescribed dose.
• If you suspect you may have overdose, call your healthcare provider.
• Do not take extra dose to make up for the missed dose.

Precaution

• Everolimus is a prescription drug and should be used under proper medical guidance and advice.
• Contraindicated in patients with clinical history of melanoma, clotting disorders, hepatic diseases.